slu pp 332 dosage FAQ

Mitochondrial adaptations induced by ERR agonism decay similarly to training-induced changes when the stimulus is removed. The Washington study tracked animals for 14 days post-treatment. Endurance capacity declined by approximately 40% within two weeks of cessation. This mirrors detraining physiology: mitochondrial density and oxidative enzyme content decrease when the transcriptional signal (training or pharmacological) stops. Maintaining adaptations likely requires continuous low-dose administration or transition to actual training to sustain ERR activation naturally.

Dosages above 30 mg/kg in rodent models did not produce toxicity but also yielded no additional endurance benefit beyond the 10 mg/kg plateau. This suggests receptor saturation. Once ERRα and ERRγ are fully occupied, excess compound circulates without binding additional targets. No adverse events were documented at 50 mg/kg in short-term (7-day) trials, but prolonged high-dose administration hasn't been evaluated. The practical implication: dosing beyond the established ceiling wastes compound without improving outcomes.

Dose the compound at the standard 10 mg/kg range and maintain your existing training protocol. The Washington University study included a trained cohort that received SLU-PP-332 alongside continued exercise. These animals showed additive improvement (approximately 120% total endurance gain vs baseline), suggesting the compound doesn't interfere with training-induced adaptation. The mechanism supports this: ERR activation amplifies the transcriptional response to training stimulus rather than replacing it. Peak benefit likely occurs when both pharmacological receptor activation and physiological training stress converge.

Verify three factors before adjusting dose: substrate purity (request HPLC verification from your supplier), reconstitution pH (test with pH strips. Target 6.5–7.5), and administration timing relative to fasting windows. SLU-PP-332 requires 10–14 days of consistent dosing before mitochondrial density changes become measurable via citrate synthase activity assays or respirometry. If all three factors check out and no response occurs by day 21, increase to 35mg and reassess at day 35.

Unreconstituted lyophilized powder tolerates ambient temperature (≤25°C) for up to 7 days without significant degradation. Pack in an insulated container with ice packs if ambient temperature exceeds 25°C. Once reconstituted, use an insulin cooler rated for 2–8°C maintenance. Models like the FRIO wallet use evaporative cooling and work without electricity for 36–48 hours. Do not freeze reconstituted peptide. Ice crystal formation ruptures peptide structure irreversibly.

Accept reduced AMPK activation (approximately 25–30% lower than fasted-state dosing) and increase sample size to compensate for higher variance. Fed-state glycogen stores blunt the ATP:AMP ratio shift that primes AMPK sensitivity. You can partially offset this by extending the dosing period from 4 weeks to 6 weeks, allowing cumulative transcriptional effects to compound despite suboptimal per-dose activation.

Skip administration and you interrupt the transcriptional cascade that drives mitochondrial biogenesis. The metabolic adaptation timeline resets partially with each missed dose because REV-ERB-mediated gene expression requires sustained receptor activation. Using SLU-PP-332 sporadically produces negligible results because the performance benefit comes from cumulative mitochondrial remodeling over weeks, not acute metabolic shifts. Missing 2–3 days per week reduces adaptation rates by 40–50% compared to daily dosing.

REV-ERB suppresses Bmal1 expression, a core component of the molecular circadian clock. Excessive suppression desynchronizes peripheral tissue clocks from the central pacemaker, manifesting as fragmented sleep and phase-shifted circadian rhythms. If you experience persistent sleep disruption or daytime fatigue within the first two weeks, reduce the dose by 30–40% and assess tolerance over another week. Circadian disruption is dose-dependent—lower doses rarely cause noticeable sleep changes, while higher doses show measurable effects in approximately 15–20% of subjects.

Discard it and prepare a fresh vial. Peptide stability at 20–25°C drops to 68% potency after 14 days, but degradation accelerates non-linearly. 48 hours at ambient temperature causes 8–12% potency loss, and you cannot visually detect this degradation. Using partially degraded compound introduces data variance that undermines reproducibility. The cost of one wasted vial is negligible compared to the cost of invalidated research timelines.

Stacking REV-ERB agonism with PPARδ agonism (GW501516) or AMPK activation (AICAR) targets overlapping but non-identical pathways. Rodent studies combining REV-ERB and PPARδ agonists showed additive effects on oxidative capacity (roughly 90–100% endurance improvement vs 70% for either alone), but also increased circadian disruption and metabolic dysregulation. Off-target effects compound faster than performance benefits when receptor systems are simultaneously activated. No published safety data exists for combination protocols.

Straight answers on reconstitution, dosing, and safety, everything you need to research with confidence. For research reference only.